featured
Impact of Gonadotropin-Releasing Hormone Antagonist vs Agonist on Clinical Safety and Oncologic Outcomes on Patients With Metastatic Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Differential Impact of Gonadotropin-Releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients With Metastatic Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
Eur Urol 2021 Jan 01;79(1)44-53, M Abufaraj, T Iwata, S Kimura, A Haddad, H Al-Ani, L Abusubaih, M Moschini, A Briganti, PI Karakiewicz, SF ShariatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.